GlassScriptPhysician profile
Allison L Rasnic
NPI 1376295097
$2,646.87
in general payments reported to CMS, 2019-2025
42 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $404 · 2024: $507 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.27 |
| Education | $183.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $282.08 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Novo Nordisk INC | $276.49 | 2022-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $189.11 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $184.87 | 2022-2025 | Imfinzi |
| Pfizer INC. | $144.81 | 2022-2025 | |
| Lilly USA, LLC | $144.02 | 2022-2025 | Jaypirca, Verzenio, Mounjaro |
| Astellas Pharma US INC | $105.96 | 2025 | Vyloy |
| Janssen Biotech, INC. | $101.04 | 2024-2025 | Darzalex, Tecvayli, Akeega |
| Aveo Pharmaceuticals, INC. | $99.54 | 2024-2025 | |
| Eisai INC. | $88.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $77.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.26 | 2024-2025 | Opdivo, Opdualag |
| Exact Sciences Corporation | $53.84 | 2023-2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $51.75 | 2024-2025 | |
| Abbvie INC. | $45.47 | 2022-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $43.57 | 2024-2025 | Cabometyx |
| Kyowa Kirin, INC. | $43.35 | 2024-2025 | Poteligeo |
| Springworks Therapeutics, INC. | $43.19 | 2025 | Gomekli |
| Tersera Therapeutics LLC | $42.71 | 2025 | Zoladex |
| Genmab U.S., INC. | $42.40 | 2024-2025 | Epkinly |
| Beigene USA, INC. | $41.23 | 2024-2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $35.03 | 2023-2025 | Ojjaara, Shingrix, Pediarix |
| Array Biopharma INC | $32.41 | 2024-2025 | Lorbrena, Braftovi |
| Amgen INC. | $29.73 | 2023-2025 | Repatha, Otezla, Otezla |
| Gilead Sciences, INC. | $28.62 | 2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.31 | 2025 | Ninlaro |
| Genzyme Corporation | $26.18 | 2025 | |
| Servier Pharmaceuticals LLC | $24.50 | 2025 | |
| Sobi, INC | $24.24 | 2025 | |
| Beone Medicines USA, INC. | $24.14 | 2025 | Brukinsa |
| Caris Mpi, INC. | $23.53 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $20.99 | 2025 | Orserdu |
| Kowa Pharmaceuticals America, INC. | $20.78 | 2022 | |
| Emd Serono, INC. | $19.28 | 2025 | |
| Incyte Corporation | $19.02 | 2025 | Jakafi |
| Nevro Corp. | $18.06 | 2023 | Senza |
| Geron Corporation | $17.40 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $16.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.53 | 2024 | Xifaxan, Trulance |
| Coherus Oncology, INC. | $13.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Rasnic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.